1. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. (January 2014) Authors: Korkosz, M; Gąsowski, J; Leszczyński, P; Pawlak-Buś, K; Jeka, S; Siedlar, M; Grodzicki, T Journal: Scandinavian journal of rheumatology Issue: Volume 43:Number 1(2014) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. (January 2014) Authors: Korkosz, M; Gąsowski, J; Leszczyński, P; Pawlak-Buś, K; Jeka, S; Siedlar, M; Grodzicki, T Journal: Scandinavian journal of rheumatology Issue: Volume 43:Number 1(2014) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Issue 2 (8th April 2009) Authors: Alten, R E; Zerbini, C; Jeka, S; Irazoque, F; Khatib, F; Emery, P; Bertasso, A; Rabbia, M; Caulfield, J P Journal: Annals of the rheumatic diseases Issue: Volume 69:Issue 2(2010) Page Start: 364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy. (28th September 2015) Authors: Iwaszko, M; Świerkot, J; Kolossa, K; Jeka, S; Wiland, P; Bogunia-Kubik, K Journal: Clinical and experimental immunology Issue: Volume 182:Number 3(2015:Dec.) Page Start: 270 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0146 Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48-week results. (15th June 2017) Authors: Suh, C-H; Khouri, E Chalouhi El; Miranda, P; Molina, F F Cons; Shesternya, P; Medina-Rodriguez, F; Wiland, P; Jeka, S; Chavez-Corrales, J; Linde, T; Hrycaj, P; Hospodarskyy, I; Abello-Banfi, M; Jaworski, J; Piotrowski, M; Park, W; Shim, SC; Lee, SJ; Lee, SY; Yoo, DH Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 824 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗